Savara Inc SVRA

SVRA Quotes by TradingView
Institutional shares held 153 Million
55.6K calls
600 puts
Total value of holdings $460M
$167K calls
$1K puts
Market Cap $343M
114,043,000 Shares Out.
Institutional ownership 134.01%
# of Institutions 140

Quarterly Institutional Activity in SVRA

Shares Bought
Shares Sold
View Transactions

Top Institutions Holding SVRA

View all
View all

Latest Institutional Activity in SVRA

Top Purchases

Q1 2025
Sg Americas Securities, LLC Shares Held: 67.1K ($202K)
15.5K Shares purchased
30.05% Added
Q1 2025
Rhumbline Advisers Shares Held: 154K ($462K)
12.1K Shares purchased
8.57% Added
Q1 2025
Farther Finance Advisors, LLC Shares Held: 32.3K ($97.3K)
6.53K Shares purchased
25.34% Added
Q1 2025
Sivia Capital Partners, LLC Shares Held: 38K ($115K)
41 Shares purchased
0.11% Added
Q4 2024
Vestal Point Capital, LP Shares Held: 10.8M ($32.4M)
2.69M Shares purchased
33.19% Added
View All Buyers

Top Sells

Q1 2025
Rothschild Investment LLC Shares Held: 90 ($271)
260 Shares sold
74.29% Reduced
Q4 2024
Adage Capital Partners Gp, L.L.C. Shares Held: 2.12M ($6.37M)
4.64M Shares sold
68.67% Reduced
Q4 2024
Wellington Management Group LLP Shares Held: 5.48M ($16.5M)
3.14M Shares sold
36.44% Reduced
Q4 2024
Affinity Asset Advisors, LLC Shares Held: 411K ($1.24M)
289K Shares sold
41.34% Reduced
Q4 2024
Janus Henderson Group PLC Shares Held: 42.4K ($128K)
203K Shares sold
82.75% Reduced
View All Sellers

About SVRA

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.

SVRA Chart by TradingView
SVRA Fundamental Data by TradingView

Insider Transactions at SVRA

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
Mar 31 2025
David A Ramsay
BUY
Open market or private purchase
Direct
150,000 +5.63%
$300,000 $2.77 P/Share
Feb 13 2025
Robert Matthew Lutz Chief Operating Officer
SELL
Payment of exercise price or tax liability
Direct
38,263 -9.57%
$76,526 $2.83 P/Share
Dec 16 2024
David L Lowrance Chief Financial Officer
SELL
Open market or private sale
Direct
25,000 -6.16%
$75,000 $3.33 P/Share
Dec 16 2024
Matthew Pauls CHIEF EXECUTIVE OFFICER
SELL
Open market or private sale
Direct
54,702 -3.44%
$164,106 $3.31 P/Share
Dec 16 2024
Richard J Hawkins
SELL
Open market or private sale
Direct
8,000 -10.63%
$24,000 $3.32 P/Share
Dec 13 2024
Anne Erickson Chief Business Officer
SELL
Payment of exercise price or tax liability
Direct
18,263 -4.03%
$54,789 $3.21 P/Share
Dec 13 2024
David L Lowrance Chief Financial Officer
SELL
Payment of exercise price or tax liability
Direct
24,350 -5.66%
$73,050 $3.21 P/Share
Dec 13 2024
David L Lowrance Chief Financial Officer
SELL
Bona fide gift
Direct
12,000 -2.71%
-
Dec 13 2024
Matthew Pauls CHIEF EXECUTIVE OFFICER
SELL
Payment of exercise price or tax liability
Direct
92,593 -5.5%
$277,779 $3.21 P/Share
Dec 12 2024
Anne Erickson Chief Business Officer
BUY
Grant, award, or other acquisition
Direct
100,000 +18.09%
-
Dec 12 2024
Braden C. Parker Chief Commercial Officer
BUY
Grant, award, or other acquisition
Direct
20,000 +16.0%
-
Dec 12 2024
David L Lowrance Chief Financial Officer
BUY
Grant, award, or other acquisition
Direct
100,000 +18.44%
-
Dec 12 2024
Matthew Pauls CHIEF EXECUTIVE OFFICER
BUY
Grant, award, or other acquisition
Direct
400,000 +19.2%
-
Dec 12 2024
Raymond Dennis Pratt Chief Medical Officer
BUY
Grant, award, or other acquisition
Direct
80,000 +19.05%
-
Dec 12 2024
Nevan C Elam
BUY
Grant, award, or other acquisition
Direct
40,000 +39.02%
-
Dec 12 2024
Richard J Hawkins
BUY
Grant, award, or other acquisition
Direct
40,000 +34.71%
-
Dec 12 2024
An Van Es Johansson
BUY
Grant, award, or other acquisition
Direct
40,000 +39.02%
-
Dec 12 2024
David A Ramsay
BUY
Grant, award, or other acquisition
Direct
40,000 +1.66%
-
Dec 12 2024
Joseph S Mc Cracken
BUY
Grant, award, or other acquisition
Direct
40,000 +13.75%
-
View All Transactions

Last 12 Months Summary

Buy / Acquisition
1.36M Shares
From 13 Insiders
Grant, award, or other acquisition 1.09M shares
Open market or private purchase 270K shares
Sell / Disposition
324K Shares
From 9 Insiders
Payment of exercise price or tax liability 224K shares
Open market or private sale 87.7K shares
Bona fide gift 12K shares

Track Institutional and Insider Activities on SVRA

Follow Savara Inc and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells SVRA shares.

Notify only if
Any

Insider Trading

Get notified when an Savara Inc insider buys or sells SVRA shares.

Notify only if
Any
Any
P - Open market or private purchase×
S - Open market or private sale×
V - Transaction voluntarily reported earlier than required×
A - Grant, award, or other acquisition×
D - Sale (or disposition) back to the issuer×
F - Payment of exercise price or tax liability×
I - Discretionary transaction×
M - Exercise of conversion of derivative security×
C - Conversion of derivative security×
E - Expiration of short derivative position×
H - Expiration (or cancellation) of long derivative position with value received×
O - Exercise of out-of-the-money derivative securities×
X - Exercise of in-the-money or at-the-money derivatives securities×
G - Bona fide gift×
L - Small Acquisition×
W - Acquisition or disposition by will or laws×
Z - Deposit into or withdrawal from voting trust×
J - Other acquisition or disposition×
K - Transaction in equity swap or similar instrument×
U - Disposition due to a tender of shares in a change of control transaction×
20 item(s) selected

News

Receive news related to Savara Inc

Choose your preferred platform and Sign Up 👇 Telegram Email
Track Activities on SVRA